Nature Communications (Feb 2020)
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
- Hiroki Tsujinaka,
- Jie Fu,
- Jikui Shen,
- Yun Yu,
- Zibran Hafiz,
- Joshua Kays,
- David McKenzie,
- Delia Cardona,
- David Culp,
- Ward Peterson,
- Brian C. Gilger,
- Christopher S. Crean,
- Jin-Zhong Zhang,
- Yogita Kanan,
- Weiling Yu,
- Jeffrey L. Cleland,
- Ming Yang,
- Justin Hanes,
- Peter A. Campochiaro
Affiliations
- Hiroki Tsujinaka
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Jie Fu
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Jikui Shen
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Yun Yu
- Graybug Vision, Inc.
- Zibran Hafiz
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Joshua Kays
- Graybug Vision, Inc.
- David McKenzie
- Graybug Vision, Inc.
- Delia Cardona
- Graybug Vision, Inc.
- David Culp
- Powered Research, LLC, Research Triangle Park
- Ward Peterson
- Graybug Vision, Inc.
- Brian C. Gilger
- Powered Research, LLC, Research Triangle Park
- Christopher S. Crean
- Graybug Vision, Inc.
- Jin-Zhong Zhang
- Graybug Vision, Inc.
- Yogita Kanan
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Weiling Yu
- Graybug Vision, Inc.
- Jeffrey L. Cleland
- Graybug Vision, Inc.
- Ming Yang
- Graybug Vision, Inc.
- Justin Hanes
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Peter A. Campochiaro
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-14340-x
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
Neovascular age-related macular degeneration and diabetic retinopathy are currently treated with repeated intravitreous injections of VEGF neutralizing proteins. Here the authors develop a microparticle-loaded tyrosine kinase inhibitor therapy, which is effective for six months after a single injection in preclinical models.
